{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:25:12Z","timestamp":1788305112478,"version":"build-2803163510"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background and Aims:<\/jats:title>\n                    <jats:p>Schizophrenia spectrum and other psychotic disorders are common disorders often requiring long-term treatment with atypical antipsychotics, which might cause metabolic dysfunctions. We aimed to study the metabolic dysfunctions with olanzapine and risperidone in patients with schizophrenia spectrum and other psychotic disorders. We also explored the incidence of new-onset metabolic syndrome and its predictors<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This was a 24-week prospective observational study conducted at a teaching hospital in North India. The patients were prescribed olanzapine or risperidone. Anthropometric measurements (waist circumference, weight, body mass index, blood pressure) and biochemical investigations (triglycerides, high-density lipoproteins, fasting plasma glucose) were recorded at baseline and after 24 weeks. Metabolic syndrome was defined using the International Diabetes Federation definition. Statistical tests used were Fisher\u2019s exact test, paired t-test, unpaired t-test, and logistic regression<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 45 patients, 30 on olanzapine and 15 on risperidone completed the study. Statistically significant changes occurred in all variables with olanzapine while with risperidone statistically significant changes occurred in all variables except waist circumference and fasting plasma glucose. Statistically greater changes in mean values between the two were noted only for high-density lipoprotein with olanzapine. 20% of patients developed metabolic syndrome with non-significant between drug differences. Baseline triglyceride predicted the development of the metabolic syndrome<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Olanzapine and risperidone cause metabolic derangements and statistically significant differences may not exist between them. Baseline triglyceride levels might predict subsequent metabolic syndrome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jfmpc.jfmpc_2161_21","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T07:41:10Z","timestamp":1653464470000},"page":"2194-2200","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Metabolic derangements with olanzapine and risperidone in schizophrenia spectrum and other psychotic disorders"],"prefix":"10.4103","volume":"11","author":[{"given":"Praveen","family":"Rikhari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhat","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harendra","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-96-20240828","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S2215-0366(19)30475-4","article-title":"The burden of mental disorders across the states of India: The Global Burden of Disease Study 1990 \u2013 2017","volume":"7","author":"Sagar","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"R3-96-20240828","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(05)66378-7","article-title":"The metabolic syndrome","volume":"365","author":"Eckel","year":"2005","journal-title":"Lancet"},{"key":"R4-96-20240828","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"R5-96-20240828","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: A systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"R6-96-20240828","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","article-title":"Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation","volume":"23","author":"Alberti","year":"2006","journal-title":"Diabet Med"},{"key":"R7-96-20240828","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.schres.2008.09.028","article-title":"Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-na\u00efve population","volume":"107","author":"Perez-Iglesias","year":"2009","journal-title":"Schizophr Res"},{"key":"R8-96-20240828","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.schres.2008.01.004","article-title":"Metabolic syndrome in first episode schizophrenia \u2014 A randomized double-blind controlled, short-term prospective study","volume":"101","author":"Saddichha","year":"2008","journal-title":"Schizophr Res"},{"key":"R9-96-20240828","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.5455\/ijmsph.2016.08032016530","article-title":"Prevalence of metabolic syndrome in drug-naive patients with schizophrenia","volume":"5","author":"Rathor","year":"2016","journal-title":"Int J Med Sci Public Health"},{"key":"R10-96-20240828","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s12291-013-0415-z","article-title":"Metabolic issues in schizophrenic patients receiving antipsychotic treatment","volume":"29","author":"Gupta","year":"2014","journal-title":"Indian J Clin Biochem"},{"key":"R11-96-20240828","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1177\/0269881108093927","article-title":"Metabolic syndrome in female patients with schizophrenia treated with second generation antipsychotics: A 3-month follow-up","volume":"23","author":"Medved","year":"2008","journal-title":"J Psychopharmacol"},{"key":"R12-96-20240828","doi-asserted-by":"crossref","first-page":"128","DOI":"10.4103\/0019-5545.82537","article-title":"Drug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (second-generation) antipsychotics","volume":"53","author":"Gautam","year":"2011","journal-title":"Indian J Psychiatry"},{"key":"R13-96-20240828","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.diabet.2008.03.003","article-title":"Insulin sensitivity, adjusted b-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: A nine-month prospective study","volume":"34","author":"Oriot","year":"2008","journal-title":"Diabetes Metab"},{"key":"R14-96-20240828","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/01.XME.0000516722.23761.98","article-title":"Metabolic dysfunction related to typical and atypical antipsychotics in drug-naive patients with nonaffective psychosis","volume":"24","author":"Asaad","year":"2017","journal-title":"Middle East Curr Psychiatry"},{"key":"R15-96-20240828","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3329\/bmrcb.v41i3.29972","article-title":"Metabolic risk factor-profile in patients on treatment with second generation antipsychotics","volume":"41","author":"Zahan","year":"2015","journal-title":"Bangladesh Med Res Counc Bull"},{"key":"R16-96-20240828","first-page":"488","article-title":"Comparison of fasting blood sugar and serum lipid profile changes after treatment with atypical antipsychotics olanzapine and risperidone","volume":"53","author":"Kaushal","year":"2012","journal-title":"Singapore Med J"},{"key":"R17-96-20240828","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1007\/s00228-014-1762-2","article-title":"Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients","volume":"70","author":"Misiak","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"R18-96-20240828","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.eurpsy.2003.06.002","article-title":"Olanzapine versus risperidone: Weight gain and elevation of serum triglyceride levels","volume":"18","author":"Garyfallos","year":"2003","journal-title":"Eur Psychiatry"},{"key":"R19-96-20240828","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s00213-006-0384-5","article-title":"Effects of typical and atypical antipsychotics on glucose\u2013 insulin homeostasis and lipid metabolism in first-episode schizophrenia","volume":"186","author":"Wu","year":"2006","journal-title":"Psychopharmacology"},{"key":"R20-96-20240828","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.4088\/JCP.v68n1113","article-title":"A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone","volume":"68","author":"Perez-Iglesias","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"R21-96-20240828","doi-asserted-by":"crossref","first-page":"814","DOI":"10.18203\/2319-2003.ijbcp20161526","article-title":"A comparative study of the effects of risperidone and olanzapine on metabolic parameters of schizophrenic patients","volume":"5","author":"Nanotkar","year":"2016","journal-title":"Int J Basic Clin Pharmacol"},{"key":"R22-96-20240828","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.schres.2009.02.006","article-title":"Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol","volume":"110","author":"Krakowski","year":"2009","journal-title":"Schizophr Res"},{"key":"R23-96-20240828","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.schres.2005.07.024","article-title":"Weight gain and lipid metabolic abnormalities induced by olanzapine in first-episode, drug-na\u00efve patients with psychotic disorders","volume":"80","author":"Sengupta","year":"2005","journal-title":"Schizophr Res"},{"key":"R24-96-20240828","first-page":"14","article-title":"An evaluation of the metabolic effects of antipsychotic medications in patients suffering from psychiatric illness","volume":"4","author":"Goswami","year":"2014","journal-title":"J App Pharm Sci"},{"key":"R25-96-20240828","first-page":"1035","article-title":"Study of biological parameters of schizophrinics during 6 months of different anti psychotics treatment","volume":"5","author":"Mubarak","year":"2018","journal-title":"J Schizophr Res"},{"key":"R26-96-20240828","first-page":"47","article-title":"Comparison of effects of olanzapine and risperidone on body mass index and blood sugar level in schizophrenic patients","volume":"53","author":"Ingole","year":"2009","journal-title":"Indian J Physiol Pharmacol"},{"key":"R27-96-20240828","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1176\/appi.ajp.160.2.290","article-title":"Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics","volume":"160","author":"Lindenmayer","year":"2003","journal-title":"Am J Psychiatry"},{"key":"R28-96-20240828","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1176\/appi.ajp.158.5.765","article-title":"A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder","volume":"158","author":"Conley","year":"2001","journal-title":"Am J Psychiatry"},{"key":"R29-96-20240828","first-page":"660","article-title":"Olanzapine-induced obesity and diabetes in Indian patients: A prospective trial comparing olanzapine with typical antipsychotics","volume":"103","author":"Guha","year":"2005","journal-title":"J Indian Med Assoc"},{"key":"R30-96-20240828","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.schres.2007.12.487","article-title":"Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE schizophrenia trial: Prospective data from phase 1","volume":"101","author":"Meyer","year":"2008","journal-title":"Schizophr Res"},{"key":"R31-96-20240828","doi-asserted-by":"crossref","first-page":"227","DOI":"10.4103\/0253-7176.119471","article-title":"Metabolic syndrome in schizophrenia","volume":"35","author":"Malhotra","year":"2013","journal-title":"Indian J Psychol Med"},{"key":"R32-96-20240828","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.psychres.2012.03.043","article-title":"Prevalence of metabolic syndrome in patients with schizophrenia in India","volume":"200","author":"Grover","year":"2012","journal-title":"Psychiatry Res"},{"key":"R33-96-20240828","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.pnpbp.2011.03.022","article-title":"The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone","volume":"35","author":"Lee","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R34-96-20240828","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1176\/appi.ajp.162.6.1217","article-title":"Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications","volume":"162","author":"Straker","year":"2005","journal-title":"Am J Psychiatry"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_2161_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:55:20Z","timestamp":1787756120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_2161_21"}},"subtitle":["A 24-week prospective study"],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_2161_21","relation":{},"ISSN":["2249-4863"],"issn-type":[{"value":"2249-4863","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}